Alto Neuroscience, Inc. (ANRO NYSE) stock market data APIs
$2.7905
0.1(3.6%)
as of July 18, 2025
Try our APIs with
free plan!
Alto Neuroscience, Inc. Financial Data Overview
Price chart is built with
Anychart
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor that is in Phase 2 proof-of-concept (POC) trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist, which is in Phase 2 POC trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor that is in Phase 1 clinical trial for the treatment of MDD. The company was incorporated in 2019 and is headquartered in Mountain View, California.
Prev. Close
2.7905
Open
2.8898
High
2.9143
Low
2.7591
52 wk Range
1.6-15.65
Market Cap
77 968 K
Shares Outstanding
27 072 K
EPS
-0.56
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Alto Neuroscience, Inc. data using free add-ons & libraries
Get Alto Neuroscience, Inc. Fundamental Data
Alto Neuroscience, Inc. Fundamental data includes:
- Net Revenue:
- EBITDA: -69 324 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-15
- EPS/Forecast: -0.57
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Alto Neuroscience, Inc. News
New
Alto Neuroscience reprices employee stock options to $2.35 per share
Alto Neuroscience , Inc. (NYSE:ANRO), a biotech company whose stock has declined nearly 80% over the past year according to InvestingPro data, announced that its Board of Directors approved a repricin...
William Blair reiterates outperform rating on Alto Neuroscience stock
Investing.com - William Blair maintained its outperform rating on Alto Neuroscience (NYSE:ANRO) stock on Thursday following mixed clinical trial results for the company’s ALTO-203 drug candidate. ...
Alto Neuroscience stock holds Buy rating at Stifel despite mixed trial data
Investing.com - Stifel maintained its Buy rating and $10.00 price target on Alto Neuroscience (NYSE:ANRO) Thursday following the company’s announcement of Phase 2 proof-of-concept results for its ...
Regeneron makes obesity push; Atai, Alto ink brain drug deals
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Today, a brief rundown of news involving Regeneron an...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
